JPWO2020068979A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020068979A5 JPWO2020068979A5 JP2021540394A JP2021540394A JPWO2020068979A5 JP WO2020068979 A5 JPWO2020068979 A5 JP WO2020068979A5 JP 2021540394 A JP2021540394 A JP 2021540394A JP 2021540394 A JP2021540394 A JP 2021540394A JP WO2020068979 A5 JPWO2020068979 A5 JP WO2020068979A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- days
- less
- treatment cycle
- cytarabine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 29
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 16
- 229960000684 cytarabine Drugs 0.000 claims description 16
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 10
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 10
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 10
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 10
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 10
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
- 229960000975 daunorubicin Drugs 0.000 claims description 3
- 238000011368 intensive chemotherapy Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000012664 BCL-2-inhibitor Substances 0.000 claims description 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims description 2
- 229940075628 hypomethylating agent Drugs 0.000 claims description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims description 2
- 229950010895 midostaurin Drugs 0.000 claims description 2
- 229960001183 venetoclax Drugs 0.000 claims 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736393P | 2018-09-25 | 2018-09-25 | |
| US62/736,393 | 2018-09-25 | ||
| US201862772372P | 2018-11-28 | 2018-11-28 | |
| US62/772,372 | 2018-11-28 | ||
| PCT/US2019/052952 WO2020068979A1 (en) | 2018-09-25 | 2019-09-25 | Low-intensity treatment of hematological disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502498A JP2022502498A (ja) | 2022-01-11 |
| JPWO2020068979A5 true JPWO2020068979A5 (https=) | 2022-09-30 |
| JP2022502498A5 JP2022502498A5 (https=) | 2022-09-30 |
Family
ID=69950910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540394A Pending JP2022502498A (ja) | 2018-09-25 | 2019-09-25 | 血液疾患の低強度治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20240252522A1 (https=) |
| EP (1) | EP3856198A4 (https=) |
| JP (1) | JP2022502498A (https=) |
| KR (1) | KR20210065962A (https=) |
| CN (1) | CN113164502A (https=) |
| AU (1) | AU2019350759A1 (https=) |
| BR (1) | BR112021005539A2 (https=) |
| CA (1) | CA3114002A1 (https=) |
| IL (1) | IL281729A (https=) |
| MX (1) | MX2021003527A (https=) |
| WO (1) | WO2020068979A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108778260A (zh) * | 2015-11-11 | 2018-11-09 | 塞拉特药物股份有限公司 | 选择白血病对象的治疗方案的分析和方法 |
| EP3856198A4 (en) * | 2018-09-25 | 2022-06-22 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
| US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
| EP4333822A1 (en) | 2021-05-03 | 2024-03-13 | Lead Discovery Center GmbH | Composition comprising an inhibitor of mitochondrial transcription |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2462376C (en) | 2001-10-03 | 2010-12-14 | Celator Technologies Inc. | Liposome loading with metal ions |
| CA2467064C (en) | 2001-11-13 | 2011-02-08 | Murray Webb | Lipid carrier compositions with enhanced blood stability |
| WO2005102359A1 (en) | 2004-04-22 | 2005-11-03 | Celator Pharmaceuticals, Inc. | Liposomal formulations of anthracycline agents and cytidine analogs |
| EP4046640A1 (en) * | 2007-02-16 | 2022-08-24 | Rotalec IP Holdings LLC | Fixed drug ratios of cytarabine to daunorubicin for treatment of hematopoietic cancers and proliferative disorders |
| EP3572071A1 (en) | 2011-10-21 | 2019-11-27 | Jazz Pharmaceuticals Research LLC | Lyophilized liposomes |
| CN108778260A (zh) * | 2015-11-11 | 2018-11-09 | 塞拉特药物股份有限公司 | 选择白血病对象的治疗方案的分析和方法 |
| BR112019001570A2 (pt) * | 2016-07-28 | 2019-07-09 | Novartis Ag | terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1 |
| WO2018101214A1 (ja) | 2016-12-01 | 2018-06-07 | Ｊｘｔｇエネルギー株式会社 | 全芳香族液晶ポリエステル樹脂 |
| EP3856198A4 (en) * | 2018-09-25 | 2022-06-22 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
| US11980636B2 (en) * | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
-
2019
- 2019-09-25 EP EP19864378.5A patent/EP3856198A4/en active Pending
- 2019-09-25 CN CN201980063289.2A patent/CN113164502A/zh not_active Withdrawn
- 2019-09-25 WO PCT/US2019/052952 patent/WO2020068979A1/en not_active Ceased
- 2019-09-25 BR BR112021005539-8A patent/BR112021005539A2/pt not_active Application Discontinuation
- 2019-09-25 AU AU2019350759A patent/AU2019350759A1/en not_active Abandoned
- 2019-09-25 MX MX2021003527A patent/MX2021003527A/es unknown
- 2019-09-25 JP JP2021540394A patent/JP2022502498A/ja active Pending
- 2019-09-25 US US17/279,556 patent/US20240252522A1/en not_active Abandoned
- 2019-09-25 CA CA3114002A patent/CA3114002A1/en active Pending
- 2019-09-25 KR KR1020217011132A patent/KR20210065962A/ko not_active Ceased
-
2021
- 2021-03-22 IL IL281729A patent/IL281729A/en unknown
- 2021-06-03 US US17/338,561 patent/US12370207B2/en active Active
-
2025
- 2025-06-24 US US19/247,599 patent/US20260014183A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saadeh | Chemotherapy‐and radiotherapy‐induced oral mucositis: Review of preventive strategies and treatment | |
| JP2022502498A5 (https=) | ||
| Oguchi et al. | Mucosa-adhesive water-soluble polymer film for treatment of acute radiation-induced oral mucositis | |
| JPH049338A (ja) | 腫瘍治療における化学療法薬の共働剤としての免疫調整剤の使用方法 | |
| JPWO2021045159A5 (https=) | ||
| CN107137417B (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2021522246A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| JPWO2020068979A5 (https=) | ||
| CA2582452A1 (en) | Pegylated liposomal doxorubicin in combination with ecteinascidin 743 | |
| WO2021037933A1 (en) | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer | |
| RU2181588C2 (ru) | Способ профилактики отсроченной рвоты | |
| JPWO2021206167A5 (https=) | ||
| JPWO2020191053A5 (https=) | ||
| RU2021111401A (ru) | Низкоинтенсивная терапия гематологических нарушений | |
| KR20210039413A (ko) | 암의 치료를 위한 병용 요법 | |
| CA3106783A1 (en) | Combination therapy for treating cancer | |
| JPWO2022218956A5 (https=) | ||
| JP2010519274A (ja) | ＴＮＦおよびα−ガラクトシルセラミドを使用する併用療法 | |
| JPWO2019211721A5 (https=) | ||
| KR20250105657A (ko) | 카피바설팁과 베네토클락스의 치료적 조합 | |
| JPWO2023120551A5 (https=) | ||
| HK40040830A (en) | Combination therapy for treating cancer | |
| JPWO2020103788A5 (https=) | ||
| TW202203942A (zh) | 血液癌之新穎治療法及新穎治療劑 |